Novartis Keen On Cardio Deals But Obesity Ship Has Sailed
The Swiss major is sticking to a bolt-on M&A strategy in its key areas and a deal in the obesity space is highly unlikely unless it involves "leapfrogging" what is already available.
The Swiss major is sticking to a bolt-on M&A strategy in its key areas and a deal in the obesity space is highly unlikely unless it involves "leapfrogging" what is already available.